New Ways to Pay for Low-Priority Drug Trials

The last decade has seen many pharmaceutical companies successfully expand their research and development operations, resulting in robust pipelines of promising new therapies in the early stages. However, with thecost of the clinical trial process for a drug today as high as $115m, drug makers must deal with the reality that they do not have the resources to develop every asset in their overflowing pipelines in a timely manner.Without the capital to invest, many promising but lower-priority therapies are sitting on a shelf, potentially losing companies billions each year in lost revenues. Delayed clinical trials result in delayed registration and patient access, plus shortened patent lives.While the impact and scale of this problem varies from company to company and across geographies and therapeutic areas, companies are employing a variety of strategies and approaches to limit their losses. Trial acceleration (for example, by moving sites or using simplifying trial design), limited operationalization and co-development deals with third parties are tactics to ensure promising new therapies are developed and approved along a profitable timeline.Yet, none of these approaches address the primary challenge – running more clinical trials with fewer resources.A new way forwardFor many forward-thinking companies, the answer to the conundrum of funding clinical trials for lower-priority drugs, is simple – partnerships.Working with clinical research organizations, universities and...

Source: EyeForPharma - June 2, 2017 Category: Pharmaceuticals Authors: Ben van der Schaaf Source Type: news